Effect of fluvoxamine on plasma risperidone concentrations

in patients with schizophrenia by D'Arrigo, Concetta et al.
Effect of fluvoxamine on plasma risperidone concentrations
in patients with schizophrenia
Concetta D’Arrigo a, Gaetana Migliardi a, Vincenza Santoro a, Letterio Morgante b,
Maria Rosaria Muscatello b, Maria Ancione c, Edoardo Spina a,∗
a Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina,
Policlinico Universitario di Messina, Via Consolare Valeria, 98125 Messina, Italy
b Department of Neurosciences, Psychiatric and Anesthesiological Sciences, University of Messina, Messina, Italy
c Centers of Mental Health, Azienda USL 5, Messina, Italy
Abstract
The effect of fluvoxamine on plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was
investigated in 11 schizophrenic patients with prevailingly negative or depressive symptoms. Additional fluvoxamine, at the dose of 100 mg/day,
was administered for 4 weeks to patients stabilized on risperidone (3–6 mg/day). Mean plasma concentrations of risperidone, 9-OH-risperidone
and the active moiety (sum of the concentrations of risperidone and 9-OH-risperidone) were not significantly modified following co-administration
with fluvoxamine. After 4 weeks, fluvoxamine dosage was increased to 200 mg/day in five patients and then maintained until the end of week
8. At final evaluation, mean plasma levels of risperidone active moiety were not modified in the six patients who were still receiving the initial
fluvoxamine dose, while concentrations increased slightly but significantly (by a mean 26% over pretreatment; P < 0.05) in the subgroup of five
subjects treated with a final dose of 200 mg/day. Fluvoxamine co-administration with risperidone was well tolerated and no patient developed
extrapyramidal side effects. These findings indicate that fluvoxamine at dosages up to 100 mg/day is not associated with clinically significant
changes in plasma risperidone concentrations. However, higher doses of fluvoxamine may elevate plasma risperidone levels, presumably as a result
of a dose-dependent inhibitory effect of fluvoxamine on CYP2D6-and/or CYP3A4-mediated 9-hydroxylation of risperidone.
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1. Introduction
Risperidone is a second-generation antipsychotic drug
with potent antagonistic properties at serotonin 5-HT2A and
dopamine D2 receptors [1]. This agent is effective in the treat-
ment of both positive and negative symptoms and, possibly,
other symptom dimensions in schizophrenia and has a lower
potential to cause extrapyramidal symptoms compared with
conventional antipsychotics [1]. However, like first-generation
antipsychotics, risperidone can induce an increase in serum pro-
lactin levels [2].
Risperidone is extensively metabolized in the liver, pri-
marily by 9-hydroxylation, yielding an active metabolite 9-
hydroxyrisperidone (9-OH-risperidone) [3]. According to in
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vivo and in vitro studies, cytochrome P450 (CYP) enzymes
CYP2D6 and, to a lesser extent, CYP3A4 are responsible for
the 9-hydroxylation of risperidone [4–7]. As 9-OH-risperidone
is approximately equipotent with the parent drug in terms of
dopamine receptor affinity, the total risperidone active moiety
(risperidone plus 9-OH-risperidone) is regarded to contribute
to the overall antipsychotic effect [8]. It is well documented
that co-administration of CYP2D6 inhibitors or CYP3A4
inhibitors/inducers may affect total plasma risperidone concen-
trations with potential clinical implications [9]. In this respect, it
has been reported that concomitant treatment with fluoxetine or
paroxetine, selective serotonin reuptake inhibitors (SSRIs) with
potent inhibitory activity on CYP2D6, may cause a significant
elevation in the plasma concentrations of the active fraction of
risperidone, possibly associated with occurrence or worsening
of extrapyramidal side effects [10–12].
Fluvoxamine is a selective serotonin reuptake inhibitor
(SSRI) widely used in the treatment of depression and other psy-
doi:10.1016/j.phrs.2005.09.005
chiatric disorders [13]. Like other SSRIs, fluvoxamine may be
co-administered with antipsychotics in schizophrenic patients
with concomitant depressive or negative symptoms [14]. Flu-
voxamine interacts with several CYP isoenzymes in vitro: it
is a potent inhibitor of CYP1A2 and CYP2C19 and a mod-
erate inhibitor of CYP2C9 and CYP3A4, while it affects
only slightly CYP2D6 activity [15–19]. Due to this non-
selective inhibition of various CYP isoenzymes, fluvoxamine
has a high potential for metabolic drug interactions in vivo
[20].
Aim of the present study was to investigate the effect of
fluvoxamine on steady-state plasma concentrations of risperi-
done and 9-OH-risperidone in patients with schizophrenia given
fluvoxamine in addition to an ongoing treatment with risperi-
done.
2. Patients and methods
2.1. Patients
Eleven outpatients (seven men and four women, aged 26–51
years) participated in the study. They had a diagnosis of
schizophrenia according to DSM IV and were stabilized on
risperidone. The protocol was approved by a local Ethics Com-
mittee and written informed consent was obtained from the
patients or their relatives.
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2.3. Drug assays
Steady-state plasma concentrations of risperidone and 9-OH-
risperidone were measured by HPLC according to the method
of Avenoso et al. [22]. The limit of quantification of the assay
was 2 ng/mL for both analytes. As analytical method allows co-
extraction of fluvoxamine, its detection in the chromatogram
was used as a measure of compliance.
2.4. Statistical analysis
Plasma concentrations of risperidone, 9-OH-risperidone and
their sum (active moiety) before and during fluvoxamine admin-
istration were compared by the Student’s t-test with Bonfer-
roni’s correction for multiple comparisons. Changes in plasma
risperidone/9-OH-risperidone ratio and in SAS scores before
and during fluvoxamine treatment were compared by the
Wilcoxon signed-rank test. Results are given in the text as
mean ± S.D. A P-value < 0.05 was regarded as statistically sig-
nificant.
3. Results
Demographic data of the patients participating to the study
and individual plasma concentrations of risperidone, 9-OH-
risperidone and active moiety before and during fluvoxamine
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a.2. Study design
All patients, stabilized on risperidone, at a constant dosage
3–6 mg/day, given as two divided daily administrations) for at
east 4 weeks, received adjunctive fluvoxamine to treat resid-
al negative symptoms, concomitant depression or both. Flu-
oxamine was administered at a dose of 100 mg/day orally
n the evening for 4 consecutive weeks. At the end of week
, the dose of fluvoxamine could be adjusted by the treat-
ng physician on the basis of the individual response and then
aintained until the end of week 8. The dosage of risperi-
one was kept constant throughout the duration of the study,
nd use of other drugs known to act as inhibitors or induc-
rs of risperidone metabolism was not allowed. Concomitant
reatment with other medication, when present, also remained
nchanged.
Blood samples for pharmacokinetic evaluations were drawn
nto heparinized tubes at 8:00 a.m. (12–13 h after the last dose
f risperidone and fluvoxamine and immediately before the
orning risperidone dose) in the week before starting flu-
oxamine (baseline) and after 4 and 8 weeks of fluvoxamine
o-administration. The plasma was separated immediately and
tored at −20 ◦C until assayed.
Tolerability was assessed by interview and a medical exam-
nation at baseline and after 4 and 8 weeks of combination
herapy, while extrapyramidal side effects were specifically eval-
ated at the same times by using the Simpson and Angus Scale
SAS) [21]. Because of the uncontrolled design, the small and
eterogeneous sample, the clinical efficacy of the combination
as not evaluated.ugmentation are reported in Table 1. After 4 weeks of fixed
uvoxamine dose, six patients were maintained on the flu-
oxamine dose of 100 mg/day, while the dose was increased
o 200 mg/day in the other five subjects. Mean plasma con-
entrations of risperidone, 9-OH-risperidone and active moi-
ty were not significantly modified during the first 4 weeks
f fluvoxamine coadministration (with all patients receiving
he dose of 100 mg/day). At week 8, in the six patients sta-
ilized on 100 mg/day, plasma concentrations of risperidone
nd metabolically derived 9-OH-risperidone did not differ from
alues at baseline and at week 4, so that levels of the active
oiety remained unchanged. In the five patients on a final
ose of 200 mg/day, mean plasma concentrations of risperi-
one increased significantly (P < 0.05) from 7 ± 2 ng/mL at
aseline to 9 ± 2 ng/mL at week 4, and to 13 ± 4 ng/mL at
eek 8, whereas levels of 9-OH-risperidone were not signif-
cantly affected. As a consequence, mean concentrations of
isperidone active moiety increased significantly (P < 0.05) from
6 ± 6 ng/mL at baseline to 50 ± 5 ng/mL at week 4, and to
8 ± 11 ng/mL at week 8 of fluvoxamine co-administration.
oreover, in this subgroup of subjects, plasma risperidone/9-
H-risperidone ratios increased significantly (P < 0.05) dur-
ng fluvoxamine cotreatment from 0.16 ± 0.05 at baseline to
.28 ± 0.05 at final evaluation.
No symptoms ascribed to risperidone toxicity were observed
hroughout the overall study period. No patient developed
xtrapyramidal side effects during adjunctive fluvoxamine treat-
ent and SAS scores remained substantially unchanged during
djunctive therapy. Two patients complained of oversedation and
ne of mild nausea during the first few days of fluvoxamine
dministration.
Table 1
Demographic data and plasma concentrations of risperidone, 9-OH-risperidone and active moiety before and during fluvoxamine treatment in 11 patients with
schizophrenia
Patient no. Sex Age
(years)
Risperidone
dose (mg/day)
Risperidone levels (ng/mL) 9-OH-risperidone levels (ng/mL) Active moiety levels (ng/mL)
Baseline Week 4 Week 8 Baseline Week 4 Week 8 Baseline Week 4 Week 8
1 F 37 4 9 7 11 28 35 40 37 42 51
2 M 45 6 4 6 8 41 32 34 45 38 42
3 M 41 4 3 3 8 34 50 40 37 53 48
4 F 34 3 7 10 8 27 27 36 34 37 44
5 M 51 4 4 6 5 36 23 33 40 29 38
6 F 27 6 8 5 9 52 57 47 60 62 56
7 M 43 4 7 9 13a 41 46 48a 48 55 61a
8 M 49 6 8 11 13a 42 36 40a 50 47 53a
9 M 26 3 4 7 8a 32 36 35a 36 43 43a
10 F 46 6 9 9 18a 39 43 54a 48 52 72a
11 M 35 6 5 7 11a 45 45 48a 50 52 59a
Mean ± S.D.b 4.7 ± 1.3 6 ± 2 7 ± 2 38 ± 7 39 ± 10 44 ± 8 46 ± 10
a Fluvoxamine dose 200 mg/day.
b Mean values at week 8 were not reported as patients were receving different fluvoxamine daily doses.
4. Discussion
Augmentation of SSRIs to risperidone is relatively com-
mon and proposed for the treatment of depressive and negative
symptoms of schizophrenia [14]. Moreover, risperidone may
be added to SSRIs to improve response in patients with major
depression or obsessive-compulsive disorder [23,24]. However,
these combinations may result in clinically relevant pharmacoki-
netic interactions as a consequence of the differential inhibitory
effects of SSRIs on CYP enzymes [25]. In this respect, formal
kinetic studies in patients with schizophrenia have reported that
paroxetine and fluoxetine increased plasma concentrations of
risperidone active moiety by 45 and 75%, respectively, sertraline
caused a minimal, dose-dependent elevation of total risperidone
concentrations, while citalopram did not modify significantly
the plasma levels of risperidone and its metabolite [10,11,26,27].
With regard to other newer antidepressants, reboxetine and mir-
tazapine do not cause significant modifications of plasma con-
centrations of risperidone active fraction [28,29].
In the current study, a 4-week addition of fluvoxamine, at
doses of 100 mg/day, to pre-existing risperidone therapy was
associated with no significant changes in plasma concentrations
of risperidone, 9-OH-risperidone and the active moiety. How-
ever, while in the six patients stabilized on 100 mg/day plasma
levels of risperidone and its metabolite were still unchanged
at week 8, in the five patients receiving the highest dose of
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trations needs to be investigated by a complete pharmacokinetic
study.
The results of the present investigation are substantially
in line with previous findings indicating that fluvoxamine, at
its usually effective dose of 100 mg/day, has a low poten-
tial for CYP2D6-mediated drug interactions [17–19]. In this
respect, in vitro research has demonstrated that fluvoxam-
ine has a weaker inhibitory effect on CYP2D6 activity as
compared to other SSRIs such as fluoxetine, norfluoxetine
and paroxetine [15,17,19]. Consistent with this, fluvoxamine,
100 mg/day, has been reported to have relatively modest in
vivo effects on CYP2D6 substrates such as dextromethorphan
[30] and desipramine [31]. To explain the minimal elevation
in total plasma risperidone levels and the associated increase
in risperidone/9-OH-risperidone ratio in the subgroup of sub-
jects receiving the highest fluvoxamine dose, it can be specu-
lated a dose-dependent inhibitory effect of fluvoxamine on the
9-hydroxylation of risperidone, presumably mediated by inhi-
bition of CYP2D6 and/or CYP3A4. In fact, fluvoxamine is a
moderate inhibitor of CYP3A4 [19], which plays a role in the
biotransformation of risperidone [6,7]. On the other hand, the
observation that in these subjects the levels of 9-OH-metabolite
did not decrease as a result of the interaction may be explained
by assuming that fluvoxamine also inhibited the further bio-
transformation of 9-OH-risperidone and/or affected alternative
routes of risperidone metabolism, such as N-dealkylation or 7-
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buvoxamine, 200 mg/day, plasma concentrations of risperidone
ere almost doubled at final evaluation as compared to baseline,
hile levels of the metabolite were substantially unchanged. As
result, a slight, but significant increase (by a mean 26%) in
lasma concentration of risperidone active fraction was observed
n this subgroup of patients at week 8 as compared to pretreat-
ent values. However, due to the limited number of patients
reated with the highest fluvoxamine dose, our findings can be
egarded as preliminary and the reported evidence of a dose-
ependent effect of fluvoxamine on plasma risperidone concen-ydroxylation [3].
While fluvoxamine appears to affect minimally and in a dose-
ependent manner the elimination of risperidone, it should be
ointed out that this agent, already at the dose of 100 mg/day,
ay cause a significant elevation of plasma concentration of var-
ous antipsychotics, such as haloperidol (1.8–4.2-fold increase),
lozapine (up to 5–10-fold) and olanzapine (up to 2-fold), due
o its potent inhibitory effect on CYP1A2, CYP2C19 and, to a
esser extent, CYP3A4, the major CYP isoforms involved in the
iotransformation of these compounds [32–35].
The combination risperidone-fluvoxamine was safe and well
tolerated and no patient experienced extrapyramidal symptoms.
However, it should be underlined that the concentrations of
risperidone active fraction reached at final evaluation by one of
the patients on the highest fluvoxamine dose were close to the
threshold values (around 70–80 ng/mL) more frequently associ-
ated with parkinsonian side effects [36].
In conclusion, our findings indicate that augmentation
of risperidone therapy with fluvoxamine at dosages up to
100 mg/day is not associated with clinically significant changes
in plasma risperidone concentrations. However, in consideration
of a dose-dependent elevation of total risperidone levels, careful
clinical observation and monitoring of plasma risperidone levels
may be of value in the management of patients receiving higher
fluvoxamine doses.
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